[1]
|
Wang, Z., Liu, H., Dou, M., Du, X., Hu, J., Su, N., Wang, Y., Zhang, R. and Li, C. (2017) The Quality Changes in Fresh Frozen Plasma of the Blood Donors at High Altitude. PLOS ONE, 12, e0176390.
https://doi.org/10.1371/journal.pone.0176390
|
[2]
|
Frisancho, A.R. (2013) Developmental Functional Adaptation to High Altitude: Review. American Journal of Human Biology, 25, 151-168. https://doi.org/10.1002/ajhb.22367
|
[3]
|
Weitz, C.A. and Garruto, R.M. (2004) Growth of Han Migrants at High Altitude in Central Asia. American Journal of Human Biology, 16, 405-419. https://doi.org/10.1002/ajhb.20042
|
[4]
|
张彦博, 汪源, 刘学良, 等. 人与高原[M]. 西宁: 青海人民出版社, 1996: 347.
|
[5]
|
张永海, 郁慕仪, 向兴利, 毛辉青. 不同海拔高度正常成人脾脏大小CT观测[J]. 高原医学杂志, 1999, 9(1): 23-27.
|
[6]
|
Donohue, J.H., Na-gorney, D.M., Grant, C.S., Tsushima, K., Ilstrup, D.M. and Adson, M.A. (1990) Carcinoma of the Gallbladder: Does Radical Resection Improve Outcome. Archives of Surgery, 125, 237-241.
https://doi.org/10.1001/archsurg.1990.01410140115019
|
[7]
|
Gukovsky, I., Li, N., Todoric, J., Gukovskaya, A. and Karin, M. (2013) Inflammation, Autophagy, and Obesity: Common Features in the Pathogenesis of Pancreatitis and Pancreatic Cancer. Gastroenterology, 144, 1199-1209.
https://doi.org/10.1053/j.gastro.2013.02.007
|
[8]
|
Yang, L. and Karin, M. (2014) Roles of Tumor Suppressors in Regulating Tumor-Associated Inflammation. Cell Death & Differentiation, 21, 1677-1686. https://doi.org/10.1038/cdd.2014.131
|
[9]
|
Roxburgh, C.S. and McMillan, D.C. (2010) Role of Systemic Inflam-matory Response in Predicting Survival in Patients with Primary Operable Cancer. Future Oncology, 6, 149-163. https://doi.org/10.2217/fon.09.136
|
[10]
|
Grivennikov, S.I., Greten, F.R and Karin, M. (2010) Immunity, Inflamma-tion, and Cancer. Cell, 140, 883-899.
https://doi.org/10.1016/j.cell.2010.01.025
|
[11]
|
Mady, M., Prasai, K., Tella, S.H., Yadav, S., Hallemeier, C.L., Rakshit, S., et al. (2020) Neutrophil to Lymphocyte Ratio as a Prognostic Marker in Metastatic Gallbladder Cancer. HPB, 22, 1490-1495.
https://doi.org/10.1016/j.hpb.2020.02.002
|
[12]
|
Jansson, H., Cornillet, M., Björkström, N.K., Sturesson, C. and Sparrelid, E. (2020) Prognostic Value of Preoperative Inflflammatory Markers in Resectable Biliary Tract Can-cer—Validation and Comparison of the Glasgow Prognostic Score and Modifified Glasgow Prognostic Score in a West-ern Cohort. European Journal of Surgical Oncology, 46, 804-810. https://doi.org/10.1016/j.ejso.2019.12.008
|
[13]
|
Saqib, R., Pathak, S., Smart, N., Nunes, Q., Rees, J., Finch Jones, M. and Poston, G. (2018) Prognostic Signifificance of Pre-Operative Inflflammatory Markers in Resected Gallbladder Cancer: A Systematic Review. ANZ Journal of Surgery, 88, 554-559. https://doi.org/10.1111/ans.14300
|
[14]
|
Biswas, T., Kang, K.H., Gawdi, R., et al. (2020) Using the Systemic Im-mune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC). International Journal of Environmental Research and Public Health, 17, 7995-8008.
https://doi.org/10.3390/ijerph17217995
|
[15]
|
Jomrich, G., Gruber, E.S., Winkler, D., et al. (2020) Systemic Im-mune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection. Journal of Gastrointestinal Surgery, 24, 610-618.
https://doi.org/10.1007/s11605-019-04187-z
|
[16]
|
Yatabe, S., Eto, K., Haruki, K., et al. (2020) Signification of Systemic Immune-Inflammation Index for Prediction of Prognosis after Resecting in Patients with Colorectal Cancer. In-ternational Journal of Colorectal Disease, 35, 1549-1555.
https://doi.org/10.1007/s00384-020-03615-w
|
[17]
|
Ozbek, E., Besiroglu, H., Ozer, K., Horsanali, M.O. and Gorgel, S.N. (2020) Systemic Immune Inflammation Index is a Promising Non-Invasive Marker for the Prognosis of the Patients with Localized Renal Cell Carcinoma. International Urology and Nephrology, 52, 1455-1463. https://doi.org/10.1007/s11255-020-02440-y
|
[18]
|
Zhang, X., Niu, Y., Wang, X., et al. (2018) Mean Platelet Vol-ume and Platelet Distribution Width Are Associated with Gallbladder Cance. Asian Pacific Journal of Cancer Prevention, 19, 351-355.
|
[19]
|
Wang, R.-T., Zhang, L.-Q., Mu, Y.-P., et al. (2015) Prognostic Significance of Preoperative Platelet Count in Patients with Gallbladder Cancer. World Journal of Gastroenterology, 21, 5303-5310.
https://doi.org/10.3748/wjg.v21.i17.5303
|
[20]
|
Javle, M., Churi, C., Kang, H.C., et al. (2015) HER2/Neu-Directed Therapy for Biliary Tract Cancer. Journal of Hematology & Oncology, 8, Article No. 58. https://doi.org/10.1186/s13045-015-0155-z
|
[21]
|
Lowery, M.A., Ptashkin, R., Jordan, E., et al. (2018) Comprehen-sive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. Clini-cal Cancer Research, 24, 4154-4161.
https://doi.org/10.1158/1078-0432.CCR-18-0078
|
[22]
|
董家鸿, 王剑明, 曾建平. 胆囊癌诊断和治疗指南(2015版) [J]. 临床肝胆病杂志, 2016, 32(3): 411-419.
|
[23]
|
Sachs, T.E., Akintorin, O. and Tseng, J. (2018) How Should Gallbladder Cancer Be Managed? Advances in Surgery, 52, 89-100. https://doi.org/10.1016/j.yasu.2018.04.003
|
[24]
|
Shirobe, T. and Maruyama, S. (2015) Laparoscopic Radical Chol-ecystectomy with Lymph Node Dissection for Gallbladder Carcinoma. Surgical Endoscopy, 29, 2244-2250. https://doi.org/10.1007/s00464-014-3932-9
|
[25]
|
Yoon, Y.-S., Han, H.-S., Cho, J.-Y., et al. (2015) Is Laparoscopy Contraindicated for Gallbladder Cancer? A 10-Year Prospective Cohort Study. Journal of the American College of Sur-geons, 221, 847-853.
https://doi.org/10.1016/j.jamcollsurg.2015.07.010
|
[26]
|
Valle, J., Wasan, H., Palmer, D.H., et al. (2010) Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. New England Journal of Medicine, 362, 1273-1281. https://doi.org/10.1056/NEJMoa0908721
|
[27]
|
Chen, C., Geng, Z., Shen, H., et al. (2016) Long-Term Outcomes and Prognostic Factors in Advanced Gallbladder Cancer: Focus on the Advanced T Stage. PLOS ONE, 11, e0166361. https://doi.org/10.1371/journal.pone.0166361
|
[28]
|
Zhou, Y., Zhang, Z., Wu, L. and Li, B. (2016) A Systematic Review of Safety and Efficacy of Hepatopancreatoduodenectomy for Biliary and Gallbladder Cancers. HPB, 18, 1-6. https://doi.org/10.1016/j.hpb.2015.07.008
|
[29]
|
Goetze, T.O. (2015) Gallbladder Carcinoma: Prognostic Factors and Therapeutic Options. World Journal of Gastroenterology, 21, 12211-12217. https://doi.org/10.3748/wjg.v21.i43.12211
|
[30]
|
刘杰, 张成武. 腹腔镜技术在胆道恶性肿瘤外科治疗中的应用[J]. 肝胆胰外科杂志, 2018, 30(2): 89-93.
|
[31]
|
Sheinfeld, W. (1947) Cholecystectomy and Partial Hepatectomy for Carcinoma of the Gall Bladder with Local Liver Extension. Surgery, 22, 48-58.
|
[32]
|
Glenn, F. and Hays, D.M. (1953) Carcinoma of the Extrahepatic Biliary Tract. Surgical Clinics of North America, 33, 479-492. https://doi.org/10.1016/S0039-6109(16)33892-0
|
[33]
|
Glenn, F. and Hays, D.M. (1954) The Scope of Radical Surgery in the Treatment of Malignant Tumors of the Extrahepatic Biliary Tract. Surgery, Gynecology and Obstetrics, 99, 529-541.
|
[34]
|
Pack, G.T., Miller, T.R. and Brasfield, R.D. (1955) Total Right Hepatic Labectomy for Cancer of the Gallbladder: Report of Three Cases. Annals of Surgery, 142, 6-16. https://doi.org/10.1097/00000658-195507000-00002
|
[35]
|
Fahim, R.B., McDonald, J.R., Richards, J.C. and Ferris, D.O. (1962) Carcinoma of the Gallbladder: A Study of Its Modes of Spread. Annals of Surgery, 156, 114-124. https://doi.org/10.1097/00000658-196207000-00021
|
[36]
|
Benson 3rd, A.B., Abrams, T.A., Ben-Josef, E., Bloom-ston, P.M., Botha, J.F., Clary, B.M., Covey, A., Curley, S.A., D’Angelica, M.I., Davila, R., Ensminger, W.D., Gibbs, J.F., Laheru, D., Malafa, M.P., Marrero, J., Meranze, S.G., Mulvihill, S.J., Park, J.O., Posey, J.A., Sachdev, J., Salem, R., Sigurdson, E.R., Sofocleous, C., Vauthey, J.N., Venook, A.P., Goff, L.W., Yen, Y. and Zhu, A.X. (2009) NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Journal of the National Comprehensive Cancer Net-work, 7, 350-391.
https://doi.org/10.6004/jnccn.2009.0027
|
[37]
|
Javle, M., Rashid, A., Churi, C., et al. (2014) Molecular Characteri-zation of Gallbladder Cancer Using Somatic Mutation Profiling. Human Pathology, 45, 701-708. https://doi.org/10.1016/j.humpath.2013.11.001
|
[38]
|
Shroff, R.T., Javle, M.M., Xiao, L., et al. (2019) Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA On-cology, 5, 824-830.
https://doi.org/10.1001/jamaoncol.2019.0270
|
[39]
|
Phelip, J.-M., Edeline, J., Blanc, J.F., et al. (2019) Modified FOLFIRINOX versus CisGem First-Line Chemotherapy for Locally Advanced Non Resectable or Metastatic Biliary Tract Cancer (AMEBICA)-PRODIGE 38: Study Protocol for a Randomized Controlled Multicenter Phase II/III Study. Digestive and Liver Disease, 51, 318-320.
https://doi.org/10.1016/j.dld.2018.11.018
|
[40]
|
Lamarca, A., Hubner, R.A., David Ryder, W. and Valle, J.W. (2014) Second-Line Chemotherapy in Advanced Biliary Cancer: A Systematic Review. Annals of Oncology, 25, 2328-2338. https://doi.org/10.1093/annonc/mdu162
|
[41]
|
Goff, L.W., Lowery, M.A., Jordan, E., et al. (2016) Second-Line Chemotherapy (CTx) Outcomes in Advanced Biliary Cancers (ABC): A Retrospective Multicenter Analysis. Journal of Clinical Oncology, 34, e15636.
https://doi.org/10.1200/JCO.2016.34.15_suppl.e15636
|
[42]
|
Lamarca, A., Palmer, D.H., Wasan, H.S., et al. (2019) A Randomised Phase III, Multi-Centre, Open-Label Study of Active Symptom Control (ASC) Alone or ASC with Ox-aliplatin / 5-FU Chemotherapy (ASC+mFOLFOX) for Patients (pts) with Locally Advanced/Metastatic Biliary Tract Cancers (ABC) Previously-Treated with Cisplatin/Gemcitabine (CisGem) Chemotherapy. Journal of Clinical Oncology, 37, e4003.
https://doi.org/10.1200/JCO.2019.37.15_suppl.4003
|
[43]
|
Lamarca, A., Barriuso, J., McNamara, M.G. and Valle, J.W. (2018) Biliary Tract Cancer: State of the Art and Potential Role of DNA Damage Repair. Cancer Treatment Reviews, 70, 168-177. https://doi.org/10.1016/j.ctrv.2018.09.002
|
[44]
|
Jain, A., Kwong, L.N. and Javle, M. (2016) Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice. Current Treatment Options in Oncology, 17, Ar-ticle No. 58. https://doi.org/10.1007/s11864-016-0432-2
|
[45]
|
Ueno, M., Chung, H.C., Nagrial, A., et al. (2018) Pembrolizumab for Advanced Biliary Adenocarcinoma: Results from the Multicohort, Phase II KEYNOTE-158 Study. Annals of Oncology, 29, VIII210.
https://doi.org/10.1093/annonc/mdy282.009
|